Vor Biopharma Inc. (VOR)

NASDAQ: VOR · IEX Real-Time Price · USD
0.937
+0.020 (2.17%)
Jul 19, 2024, 1:30 PM EDT - Market open
2.17%
Market Cap 63.96M
Revenue (ttm) n/a
Net Income (ttm) -120.23M
Shares Out 68.26M
EPS (ttm) -1.77
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 120,441
Open 0.932
Previous Close 0.917
Day's Range 0.905 - 0.967
52-Week Range 0.900 - 3.480
Beta -0.34
Analysts Strong Buy
Price Target 12.50 (+1,234.19%)
Earnings Date Aug 8, 2024

About VOR

Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies. The company is also developing Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, which are under preclinic... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Feb 5, 2021
Employees 168
Stock Exchange NASDAQ
Ticker Symbol VOR
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for VOR stock is "Strong Buy." The 12-month stock price forecast is $12.5, which is an increase of 1,234.19% from the latest price.

Price Target
$12.5
(1,234.19% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., July 09, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that, effective as of July 1, 2024, the Compensation Co...

9 days ago - GlobeNewsWire

Vor Bio Reports First Quarter 2024 Financial Results and Provides Company Update

CAMBRIDGE, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period ended March ...

2 months ago - GlobeNewsWire

Vor Bio to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming inves...

2 months ago - GlobeNewsWire

Vor Bio Appoints Accomplished Oncology and Cancer Immunotherapy R&D Executive, Fouad Namouni, M.D., to its Board of Directors

CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the appointment of Fouad Namouni, M.D., to its Board of ...

2 months ago - GlobeNewsWire

Vor Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update

CAMBRIDGE, Mass., March 20, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period and full y...

4 months ago - GlobeNewsWire

Vor Bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

CAMBRIDGE, Mass., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in a fireside chat and host vi...

5 months ago - GlobeNewsWire

Vor Bio Doses First AML Patient with VCAR33 (ALLO) and Provides Corporate Update

CAMBRIDGE, Mass., Jan. 17, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, announced today it has dosed the first patient in VBP301, its Phase 1/2...

6 months ago - GlobeNewsWire

Vor Bio to Participate in the JMP Securities Hematology and Oncology Summit

CAMBRIDGE, Mass., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in a fireside chat and host vi...

8 months ago - GlobeNewsWire

Vor Bio Presents Positive Data Update on Trem-cel at HSCT² Conference

CAMBRIDGE, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today presented updated clinical data from patients treated in VBP101, ...

9 months ago - GlobeNewsWire

Vor Bio Reports Third Quarter 2023 Financial Results and Provides Company Update

CAMBRIDGE, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period ended Septe...

9 months ago - GlobeNewsWire

Multiple Clinical and Preclinical Presentations at ASH 2023 Highlight Vor Bio's Novel eHSC and CAR-T Platform

CAMBRIDGE, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that preclinical and clinical data supporting the Compa...

9 months ago - GlobeNewsWire

Vor Bio Reports Second Quarter 2023 Financial Results and Provides Company Update

CAMBRIDGE, Mass., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period ended June ...

1 year ago - GlobeNewsWire

Vor Bio to Participate in the Wedbush PacGrow Healthcare Conference

CAMBRIDGE, Mass., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, will host in-person 1x1 investor meetings at the 2023 Wedbush PacGrow H...

1 year ago - GlobeNewsWire

Top 5 Health Care Stocks That Could Lead To Your Biggest Gains In July - Cibus (NASDAQ:CBUS), Bellerophon Therapeutics (NASDAQ:BLPH)

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Other symbols: BLPHCBUSLUCYPBLA
1 year ago - Benzinga

Successful Primary Engraftment of Trem-cel in First Five AML Patients Demonstrates Promise of Vor Bio's Platform

CAMBRIDGE, Mass., June 09, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today presented updated clinical data from patients treated in VBP101, ...

1 year ago - GlobeNewsWire

Vor Bio to Participate in the Goldman Sachs Healthcare Conference

CAMBRIDGE, Mass., June 05, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, will present and host in-person 1x1 investor meetings at the Goldman Sa...

1 year ago - GlobeNewsWire

Vor Bio Reports First Quarter 2023 Financial Results and Provides Company Update

CAMBRIDGE, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period ended March ...

1 year ago - GlobeNewsWire

Vor Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Company Update

CAMBRIDGE, Mass., March 23, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period and full y...

1 year ago - GlobeNewsWire

First AML Patient Transplanted with Vor Bio's Trem-cel Demonstrated Durable Engraftment through Multiple Mylotarg™ Cycles at Initial Dose Level

CAMBRIDGE, Mass., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, presented clinical data from VBP101, its Phase 1/2a multicenter, open-l...

1 year ago - GlobeNewsWire

Vor Bio to Present Clinical Data from First Patient Treated with Trem-cel at 2023 Tandem Meetings

CAMBRIDGE, Mass., Jan. 19, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that clinical data from the first patient treated in VB...

1 year ago - GlobeNewsWire

Vor Bio to Present at B. Riley Securities' 3rd Annual Oncology Conference

CAMBRIDGE, Mass., Jan. 12, 2023 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate virtually in B. Riley Se...

1 year ago - GlobeNewsWire

Vor Bio Prices Underwritten Offering of Common Stock and Concurrent Private Placement for Aggregate Proceeds of $115.8 Million

CAMBRIDGE, Mass., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the pricing of an underwritten offering and a private p...

1 year ago - GlobeNewsWire

First AML Patient Successfully Transplanted with Vor Bio's Investigational Trem-cel (VOR33) and Tolerated Mylotarg™

CAMBRIDGE, Mass., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced initial clinical data from VBP101, its Phase 1/2a multi...

1 year ago - GlobeNewsWire

Vor Bio Reports Third Quarter 2022 Financial Results and Provides Company Update

CAMBRIDGE, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period ended Septe...

1 year ago - GlobeNewsWire

Vor Bio Appoints Eyal C. Attar, M.D.

CAMBRIDGE, Mass., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that Eyal C. Attar, M.D., has joined Vor Bio as Chief M...

1 year ago - GlobeNewsWire